Vascular Graft Market Size, Share, Opportunities, And Trends By Source (Synthetic, Semi-Synthetic, Natural), By Indication (Cardiovascular, Renal Diseases, Aneurysms, Others), By End-User (Hospitals And Clinics, Ambulatory Surgical Centres), And By Geography - Forecasts From 2025 To 2030

Vascular Graft Market Size:

The vascular graft market is expected to grow from USD 1.579 billion in 2025 to USD 2.038 billion in 2030, at a CAGR of 5.23%.

The key factor driving the global vascular graft market growth is the increasing number of dialysis procedures and the growing chronic kidney disease (CKD). According to a report by Kidney International Supplement Journal in April 2022, chronic kidney disease affected over 10% of the population worldwide. The increasing cases of kidney failure are providing an edge for the global vascular graft industry. For instance, as per the 2022 articles published by the National Institute of Diabetes and Digestive and Kidney Disease, nearly 8,08,000 people in the United States are suffering from End-Stage Kidney Disease (ESKD) out of which 69% are on dialysis and 31% of the people need a kidney transplant. The increasing number of dialysis is increasing the growth of the global vascular graft market.

Vascular Graft Market Growth Drivers:

• The increasing number of heart strokes

The increasing rate of heart disease and strokes is also increasing the requirement for vascular grafts. Furthermore, there is an increasing prevalence of coronary artery bypass grafting along with the reconstructions of the microvascular flap-based tissue which is also resulting in the rising use of vascular graft. Coronary artery bypass grafting (CABG) stands out as one of the most commonly employed techniques in cardiac surgical procedures on a global scale, as reported by the Journal of Thoracic Disease. The CABG has an annual volume of 2,00,000 isolated cases in the United States and an average incidence rate of 62 per 1,00,000 inhabitants in Western Europe.  According to Centers for Disease Control and Prevention (CDC) data published in April 2022, more than 795,000 people suffer from strokes in the United States. Of these 1,85,000 people already had a stroke once or twice and 6,10,000 people suffered from stroke for the first time. As the number of strokes rises, so will the demand for effective therapies such as coronary artery bypass surgery and improved cardiovascular devices. Over the forecast period, this is expected to fuel global vascular graft market expansion.

• Growing prevalence of chronic kidney diseases

Chronic kidney disease often progresses to end-stage renal disease (ESRD), where the kidneys no longer function effectively. Hemodialysis, a common treatment for ESRD, involves the use of an external machine to filter waste and excess fluids from the blood. To facilitate hemodialysis, patients require reliable vascular access points where blood can be efficiently withdrawn, filtered, and returned to the body. Vascular grafts are frequently used to create arteriovenous fistulas (AVFs) or arteriovenous grafts (AVGs) for this purpose. An increase in the number of patients requiring hemodialysis due to CKD can lead to a higher demand for vascular grafts to create and maintain these access points.

• The United States is anticipated to be the largest growing market during the forecast period

The United States is witnessing an increase in its aging population, and with age comes an increased risk of vascular diseases such as atherosclerosis, which can lead to the narrowing or blockage of blood vessels. As a result, there is a global vascular graft market is growing to address these issues and restore blood flow. Furthermore, the prevalence of conditions like coronary artery disease, peripheral artery disease, and aneurysms has been on the rise. These conditions often require surgical interventions, such as bypass procedures or aneurysm repairs, which involve the use of vascular grafts.

Vascular Graft Market Key Developments:

• In May 2022, UC Davis Professor Aijun Wang secured a substantial $3 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the development of an innovative and long-lasting vascular device tailored for hemodialysis patients undergoing treatment for kidney failure.

Segmentation:

• By Source
  • Synthetic
  • Semi-Synthetic
  • Natural
• By Indication
  • Cardiovascular
  • Renal Disease
  • Aneurysms
  • Others
• By End-User
  • Hospital & Clinics
  • Ambulatory Surgical Centers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Taiwan
    • Thailand
    • Others

---

1.  INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. GLOBAL VASCULAR GRAFT MARKET ANALYSIS, BY SOURCE 

5.1. Introduction

5.2. Synthetic

5.3. Semi-Synthetic

5.4. Natural

6. GLOBAL VASCULAR GRAFT MARKET ANALYSIS, BY INDICATION 

6.1. Introduction

6.2. Cardiovascular

6.3. Renal Disease

6.4. Aneurysms

6.5. Others

7. GLOBAL VASCULAR GRAFT MARKET ANALYSIS, BY END-USER

7.1. Introduction 

7.2. Hospital & Clinics

7.3. Ambulatory Surgical Centers

8. GLOBAL VASCULAR GRAFT MARKET ANALYSIS, BY GEOGRAPHY 

8.1. Introduction

8.2. North America

8.2.1. By Source

8.2.2. By Indication

8.2.3. By End-User

8.2.4. By Country

8.2.4.1. United States

8.2.4.2. Canada

8.2.4.3. Mexico

8.3. South America

8.3.1. By Source

8.3.2. By Indication

8.3.3. By End-User

8.3.4. By Country

8.3.4.1. Brazil

8.3.4.2. Argentina

8.3.4.3. Others

8.4. Europe

8.4.1. By Source

8.4.2. By Indication 

8.4.3. By End-User

8.4.4. By Country

8.4.4.1. UK

8.4.4.2. France

8.4.4.3. Germany

8.4.4.4. Italy

8.4.4.5. Others

8.5. Middle East and Africa

8.5.1. By Source

8.5.2. By Indication

8.5.3. By End-User

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.2. Israel

8.5.4.3. Others

8.6. Asia Pacific

8.6.1. By Source

8.6.2. By Indication

8.6.3. By End-User

8.6.4. By Country

8.6.4.1. Japan

8.6.4.2. China

8.6.4.3. India

8.6.4.4. Australia

8.6.4.5. South Korea

8.6.4.6. Thailand

8.6.4.7. Taiwan

8.6.4.8. Indonesia

8.6.4.9. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Market Share Analysis

9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

10.1. Getinge Group 

10.2. W.L. Gore & Associates

10.3. B. Braun Melsungen AG

10.4. LeMaitre Vascular Inc.

10.5. Abbott Laboratories

10.6. Cook Medical

10.7. Terumo Medical Corporation

10.8. Cryolife

10.9. Medtronic PLC

10.10. Endologix Inc.

Getinge Group

W.L. Gore & Associates

B. Braun Melsungen AG

LeMaitre Vascular Inc.

Abbott Laboratories

Cook Medical

Terumo Medical Corporation

Cryolife

Medtronic PLC

Endologix Inc.